Navigation Links
Westaim announces sale of iFire Technology Ltd. assets
Date:10/17/2008

CALGARY, Oct. 17 /PRNewswire-FirstCall/ - The Westaim Corporation announced today a purchase and sale agreement between its wholly owned subsidiary iFire Technology Ltd. and CTS Group Limited. Under the agreement, iFire will sell its equipment, patents and intellectual property for net proceeds of approximately US$8.0 million. The sale is subject to several conditions, including iFire obtaining certain Government of Canada consents and approvals, which are expected to be obtained by mid-November. CTS Group is a Canadian-Chinese joint venture with established operations in Henan province, People's Republic of China.

"iFire management has worked very hard over the past few months to bring this transaction to completion," said Drew Fitch, President & CEO of Westaim. "The sale of iFire's assets will provide Westaim with additional cash resources as the company pursues its goal of strategically transitioning into a new sector."

Westaim previously announced it has entered into a reorganization agreement where it will acquire, subject to shareholder approval, several closely held and profitable businesses that provide products and services in the growing western Canadian construction industry. An information circular was mailed to shareholders on October 15th in advance of a special meeting of shareholders to be held on November 21, 2008. Westaim continues to hold a 74.5 percent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS).

The Westaim Corporation's common shares are listed on The Toronto Stock Exchange under the trading symbol WED.

This news release contains forward-looking statements. These statements are based on current expectations that are subject to risks and uncertainties, and Westaim can give no assurance that these expectations are correct. Various factors could cause actual results to differ materially from those projected in such statements, including but not limited to statements regarding the sale of assets, cash resources to be realized from the sale of assets, shareholder and other approvals to which acquisition of businesses or sales of assets are subject, conditions upon the sale of assets, Westaim's strategic transition to a new sector, and the acquisition of businesses. Westaim disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise. Accordingly, readers are advised not to place undue reliance on forward-looking statements, and should not rely on this information at any date other than the date of this news release. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE Westaim Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Westaim announces 2008 second quarter results
2. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Second Quarter Results
3. Westaim announces 2008 first quarter results
4. Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
5. Westaim announces 2007 year-end results
6. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
7. Westaim reduces ABCP exposure
8. Westaim announces 2007 third quarter results
9. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
10. The Westaim Corporation update on status of short-term investments
11. US Oncologys Innovent Oncology Division Announces First Agreement Between Rocky Mountain Cancer Centers and Colorado Public Employees Retirement Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
(Date:7/20/2017)... ... July 20, 2017 , ... LINET, an international leader ... to their product line: the AVE 2 birthing bed. , Perfectly suitable for labor, ... new level of comfort and efficiency to every phase of childbirth. The AVE 2 ...
(Date:7/20/2017)... TX (PRWEB) , ... July 19, 2017 , ... At ... the availability of temporomandibular joint (TMJ) treatment and dental implants in Waco, ... TRIOS® intraoral scanner and the T-Scan™ by Tekscan®, they can capture details in the ...
(Date:7/20/2017)... ... July 19, 2017 , ... Adolfson ... healthcare project manager, Josh Christensen. As a leader in healthcare construction, AP has ... its healthcare resume in the Midwest with Josh now on board. , ...
(Date:7/20/2017)... ... ... a fun-filled, action-packed memoir of adventures. “Fidget” is the creation of published author, Carol ... summa cum laude graduate of Gardner Webb University. She has won numerous awards during ... public school, Lynn continued to pursue her love for music through playing piano, harp, ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017  The tenth annual BioPharm ... MA at the Sheraton Boston Hotel, September ... access to global decision makers and innovative biotech startup ... science leaders during two impactful days. BioPharm America is ... with additional networking opportunities with 4,500+ life science industry ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
Breaking Medicine Technology: